An in vivo evaluation of the ontogeny of stereoselective fluoxetine metabolism and disposition in lambs from birth to one year of age

1. The objective was to determine the ontogeny of stereoselective fluoxetine (FX) disposition in postnatal sheep from newborn to adulthood. 2. Catheters were implanted in a carotid artery and jugular vein. FX was administered intravenously, followed by serial arterial blood and cumulative urine collection. The concentrations of R,S-FX and R,S-norfluoxetine (R,S-NFX) in samples were measured using a validated enantioselective LC/MS/MS analytical method. 3. The metabolism of FX at 4.2 ± 0.4 days was limited compared to adults, but had developed compared to the fetus. Total body clearance (ClTB) did not significantly increase up to 33.6 ± 0.9 days, but significantly increased at 98.5 ± 2.0 days, with no further changes up to 397.3 ± 8.5 days. Up to 13.4 ± 0.8 days, the disposition of FX included Phase I metabolism to NFX and trifluoromethylphenol (TFMP), and renal elimination. At 32.9 ± 0.9 days, metabolism included Phase II conjugates of FX and NFX. Renal elimination of these compounds was low. 4. The elimination of FX increased in a non-linear manner during the first year in sheep. The metabolism and disposition of FX and NFX in plasma and urine were stereoselective and this appeared due to both stereoselective protein binding and metabolism.

Medienart:

E-Artikel

Erscheinungsjahr:

2019

Erschienen:

2019

Enthalten in:

Zur Gesamtaufnahme - volume:49

Enthalten in:

Xenobiotica; the fate of foreign compounds in biological systems - 49(2019), 11 vom: 08. Nov., Seite 1360-1372

Sprache:

Englisch

Beteiligte Personen:

Chow, Timothy W [VerfasserIn]
Nguyen, Tuan-Anh [VerfasserIn]
Riggs, K Wayne [VerfasserIn]
Rurak, Dan W [VerfasserIn]

Links:

Volltext

Themen:

01K63SUP8D
Blood Proteins
Development
Fluoxetine
Journal Article
K8D70XE2F4
Lambs
Metabolism
Norfluoxetine
Pharmacokinetics
Video-Audio Media

Anmerkungen:

Date Completed 05.02.2020

Date Revised 05.02.2020

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1080/00498254.2018.1563922

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM292163649